- In May 2026, Recursion Pharmaceuticals reported first-quarter 2026 results showing sales of US$6.3 million and revenue of US$6.47 million, alongside a net loss of US$117.5 million and basic loss per share from continuing operations of US$0.22, while also participating in Fierce Biotech Week 2026 in Boston.
- A separate update from Altitude Lab, the biotech accelerator co-founded by Recursion, highlighted that its portfolio companies have collectively raised over US$205 million since 2020, with several progressing into clinical trials, signing global pharma deals, and moving toward commercialization.
- Next, we’ll explore how Altitude Lab’s early-stage funding progress and clinical momentum could influence Recursion’s broader investment narrative.
Uncover the next big thing with 27 elite penny stocks that balance risk and reward.
Recursion Pharmaceuticals Investment Narrative Recap
To own Recursion, you need to believe its AI driven drug discovery engine can ultimately justify years of sizeable losses and dilution risk. The latest Q1 2026 results, with revenue of US$6.47 million and a net loss of US$117.5 million, underline that the most important near term catalyst remains clinical and partnership progress, while the key risk is continued heavy cash burn. This quarter’s numbers do not materially change that picture.
Against that backdrop, Altitude Lab’s update that its portfolio has raised over US$205 million since 2020, with several companies entering trials and signing pharma deals, is especially relevant. It reinforces that Recursion sits inside a broader early stage biotech ecosystem that is starting to convert ideas into clinical assets, which could support future collaboration opportunities and help validate Recursion’s technology driven investment story.
Yet, despite this ecosystem progress, investors should still be aware that...
Read the full narrative on Recursion Pharmaceuticals (it's free!)
Recursion Pharmaceuticals’ narrative projects $220.9 million revenue and $35.5 million earnings by 2028.
Uncover how Recursion Pharmaceuticals' forecasts yield a $7.00 fair value, a 146% upside to its current price.
Exploring Other Perspectives
Some of the lowest analysts took a more cautious view, assuming revenue of about US$102 million and earnings of only US$16.6 million by 2028, which contrasts with the recent Q1 loss and highlights how opinions on Recursion’s cash burn and AI advantage can differ widely and may shift again as investors digest this latest update.
Explore 6 other fair value estimates on Recursion Pharmaceuticals - why the stock might be worth over 3x more than the current price!
Reach Your Own Conclusion
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Recursion Pharmaceuticals research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
- Our free Recursion Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Recursion Pharmaceuticals' overall financial health at a glance.
Ready To Venture Into Other Investment Styles?
Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:
- AI is about to change healthcare. These 29 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
- The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
- We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com